Peter Greenberg

Hematologist

Medical oncologist, Leukemia specialist

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Medical Education: George Washington University (1963) DC

Fellowship: Stanford University School of Medicine (1971) CA

Residency: Barnes Hospital (1965) MO

Residency: Stanford University School of Medicine (1968) CA

Board Certification: Hematology, American Board of Internal Medicine (1976)

Board Certification: Internal Medicine, American Board of Internal Medicine (1970)

Internship: Barnes Hospital (1964) MO

B.A., Johns Hopkins University, Biological Sciences (1959)

M.D., George Washington U Med School, Medicine (1963)

Honors & Awards

International Prize for outstanding research in myelodysplastic syndromes (MDS), J.P. McCarthy Foundation (1997)

Administrative Appointments

Coordinator, International Working Group for Prognosis in MDS, 2009

Chair, National Comprehensive Cancer Network Myelodysplasitic Syndromes Practice Guidelines Panel, 1997

Director, Stanford MDS Center, 1998

Head, Hematology Section, VA Palo Alto Health Care System, 1979

Acting Chief, Medical Service, VA Palo Alto Health Care System, 1978

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
Koreth, J., Pidala, J., Perez, W. S., Deeg, H. J., Garcia-Manero, G., & Cutler, C. (2013). Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. Journal of clinical oncology , 31(21), 2662-2670.

Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
Pang, W. W., Pluvinage, J. V., Price, E. A., Sridhar, K., Arber, D. A., & Weissman, I. L. (2013). Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(8), 3011-3016.

Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
Koontz, M. Z., Horning, S. J., Balise, R., Greenberg, P. L., Rosenberg, S. A., & Advani, R. H. (2013). Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. Journal of clinical oncology , 31(5), 592-598.

Specific plasma autoantibody reactivity in myelodysplastic syndromes
Mias, G. I., Chen, R., Zhang, Y., Sridhar, K., Sharon, D., & Greenberg, P. L. (2013). Specific plasma autoantibody reactivity in myelodysplastic syndromes. Scientific Reports , 3.

The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features.
Greenberg, P. L. (2013). The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features. Journal of the National Comprehensive Cancer Network : JNCCN, 11(7), 877-85.

Reduced rRNA expression and increased rDNA promoter methylation in CD34(+) cells of patients with myelodysplastic syndromes
Raval, A., Sridhar, K. J., Patel, S., Turnbull, B. B., Greenberg, P. L., & Mitchell, B. S. (2012). Reduced rRNA expression and increased rDNA promoter methylation in CD34(+) cells of patients with myelodysplastic syndromes. BLOOD, 120(24), 4812-4818.

Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., & Haase, D. (2012). Revised International Prognostic Scoring System for Myelodysplastic Syndromes. BLOOD, 120(12), 2454-2465.

Molecular and genetic features of myelodysplastic syndromes
Greenberg, P. L. (2012). Molecular and genetic features of myelodysplastic syndromes. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 34(3), 215-222.

Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes
Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Yk., & Snyder, M. (2012). Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes. CELL, 148(6), 1293-1307.

Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow
Flores-Figueroa E, Varma S, Montgomery K, Greenberg P, & Gratzinger D. (2012). Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow. Lab Investigation, 92.

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na
Seetharam, M., Fan, A. C., Tran, M., Xu, L., Renschler, J. P., & Greenberg, P. L. (2012). Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. LEUKEMIA RESEARCH, 36(1), 98-103.

Myelodysplastic Syndromes: Dissecting the Heterogeneity
Greenberg, P. L. (2011). Myelodysplastic Syndromes: Dissecting the Heterogeneity. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1937-1938.

Myelodysplastic Syndromes
Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., & Westervelt, P. (2011). Myelodysplastic Syndromes. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(1), 30-56.

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes
Greenberg, P. L., Koller, C. A., Cabantchik, Z. I., Warsi, G., Glynos, T., & Schiffer, C. (2010). Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. LEUKEMIA RESEARCH, 34(12), 1560-1565.

Current therapeutic approaches for patients with myelodysplastic syndromes
Greenberg, P. L. (2010). Current therapeutic approaches for patients with myelodysplastic syndromes. BRITISH JOURNAL OF HAEMATOLOGY, 150(2), 131-143.

Relationship of differential gene expression profiles in CD34(+) myelodysplastic syndrome marrow cells to disease subtype and progression
Sridhar, K., Ross, D. T., Tibshirani, R., Butte, A. J., & Greenberg, P. L. (2009). Relationship of differential gene expression profiles in CD34(+) myelodysplastic syndrome marrow cells to disease subtype and progression. BLOOD, 114(23), 4847-4858.

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Greenberg, P. L., Sun, Z., Miller, K. B., Bennett, J. M., Tallman, M. S., & Rowe, J. M. (2009). Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). BLOOD, 114(12), 2393-2400.

A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes
Gotlib, J., Lavori, P., Quesada, S., Stein, R. S., Shahnia, S., & Greenberg, P. L. (2009). A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. AMERICAN JOURNAL OF HEMATOLOGY, 84(1), 15-20.

NCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes
Greenberg, Pl., Rigsby C, Stone RM, Deeg J, Gore S, & Kumar R. (2009). NCCN Task Force Report: Transfusion and Iron Overload in Patients with Myelodysplastic Syndromes. J Nat Comp Cancer Network, 7((Suppl 9).

Myelodysplastic syndromes.
Greenberg, P. L., Attar, E., Battiwalla, M., Bennett, J. M., Bloomfield, C. D., & Westervelt, P. (2008). Myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network , 6(9), 902-926.

The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Greenberg, P. L., Cosler, L. E., Ferro, S. A., & Lyman, G. H. (2008). The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. Journal of the National Comprehensive Cancer Network , 6(9), 942-953.

International MDS Risk Analysis Workshop (IMRAW)/IPSS Re-analyzed: Impact of cytopenias on clinical outcomes in Myelodysplastic Syndrome
Kao JM, McMillan A, & Greenberg PL. (2008). International MDS Risk Analysis Workshop (IMRAW)/IPSS Re-analyzed: Impact of cytopenias on clinical outcomes in Myelodysplastic Syndrome. Am J Hematology.

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF
Park S, Grabar S, Kelaidi C, Greenberg P, & et al. (2008). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF. Blood, 111.

Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.
Sloand EM, Wu C, Greenberg P, & et al. (2008). Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol, 26.

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-year prospective study.
Porter J, Galanello R, Saglio S, Greenberg P, & et al. (2008). Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-year prospective study. Eur J Haematol, 80.

Phase II Study of Lenalidomide in Transfusion-Dependent, Low and Intermediate-1-Risk Myelodysplastic Syndromes with Normal and Abnormal Karyotypes Other than Deletion 5q.
Raza A, Reeves JE, Feldman EJ, Dewald GW, Bennett JM, & et al. (2008). Phase II Study of Lenalidomide in Transfusion-Dependent, Low and Intermediate-1-Risk Myelodysplastic Syndromes with Normal and Abnormal Karyotypes Other than Deletion 5q. Blood, 111.

Myelodysplastic Syndromes: Impact of recently analyzed variables for modifying current classification methods
Kao JM, & Greenberg PL. (2007). Myelodysplastic Syndromes: Impact of recently analyzed variables for modifying current classification methods. Clinical Leukemia, 1.

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus Statements and Report from a Working Conference
Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, & et al. (2007). Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus Statements and Report from a Working Conference. Leukemia Research, 31.

Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion.
List A, Dewald G, Bennett J, Giagounidis A, Raza A, & et al. (2006). Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion. New Eng J Med, 355.

Myelodysplastic syndromes clinical practice guidelines in oncology.
Greenberg, P. L., Baer, M. R., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., & Tallman, M. S. (2006). Myelodysplastic syndromes clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(1), 58-77.

A phase II study of the farnesyltransferase inhibitor tipifarnib in elderly patients with previously untreated poor-risk acute myeloid leukemia
Lancet J, Gojo I, Gotlib J, Greenberg PL, & et al. (2006). A phase II study of the farnesyltransferase inhibitor tipifarnib in elderly patients with previously untreated poor-risk acute myeloid leukemia. Blood, 108.

Myelodysplastic Syndromes: Clinical and Biological Advances
Greenberg, Pl. E. (2006). Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge University Press, Cambridge, England.

Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Greenberg, P. L. (2006). Myelodysplastic syndromes: iron overload consequences and current chelating therapies. Journal of the National Comprehensive Cancer Network , 4(1), 91-96.

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
Cheson BD, Greenberg PL, Bennett JM, & et al. (2006). Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108.

Management of patients with higher risk myelodysplastic syndromes
Fukumoto, J. S., & Greenberg, P. L. (2005). Management of patients with higher risk myelodysplastic syndromes. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 56(2), 179-192.

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., & Rowe, J. M. (2004). Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). JOURNAL OF CLINICAL ONCOLOGY, 22(6), 1078-1086.

A Decision Analysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes: Delayed Transplantation for Low Risk Myelodysplasia is Associated with Improved Outcome
Cutler C, Lee SJ, Greenberg P, & et al. (2004). A Decision Analysis of Allogeneic Bone Marrow Transplantation for the Myelodysplastic Syndromes: Delayed Transplantation for Low Risk Myelodysplasia is Associated with Improved Outcome. Blood, 104.

Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study
Cherry, A. M., Brockman, S. R., Paternoster, S. F., Hicks, G. A., Neuberg, D., & DeWald, G. W. (2003). Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. LEUKEMIA RESEARCH, 27(12), 1085-1090.

Novel biospecific agents for the treatment of myelodysplastic syndromes.
Gotlib J, & Greenberg P. (2003). Novel biospecific agents for the treatment of myelodysplastic syndromes. J Nat Comprehensive Cancer Network, 1.

Myelodysplastic syndromes.
Greenberg, P. L., Young, N. S., & Gattermann, N. (2002). Myelodysplastic syndromes. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 136-161.

Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines
Greenberg, P. (2001). Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines. ANNALS OF THE RHEUMATIC DISEASES, 60, III41-III42.

Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes
Greenberg, P. (2001). Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes. LANCET, 357(9262), 1059-1060.

The Myelodysplastic Syndromes , .
Greenberg PL. (2000). The Myelodysplastic Syndromes , . Hematology: Basic Principles and Practice. 3rd Ed., Hoffman R, Benz E, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P, Eds. Churchill Livingstone, NY,.

Prognostic scoring systems for risk assessment in myelodysplastic syndromes.
Greenberg, P. L., Sanz, G. F., & Sanz, M. A. (1999). Prognostic scoring systems for risk assessment in myelodysplastic syndromes. Forum (Genoa, Italy), 9(1), 17-31.

Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment
Greenberg, P. L. (1998). Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. LEUKEMIA RESEARCH, 22(12), 1123-1136.

Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression
Davis, R. E., & Greenberg, P. L. (1998). Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. LEUKEMIA RESEARCH, 22(9), 767-777.

Risk factors and their relationship to prognosis in myelodysplastic syndromes
Greenberg, P. L. (1998). Risk factors and their relationship to prognosis in myelodysplastic syndromes. LEUKEMIA RESEARCH, 22, S3-S6.

NCCN Practice Guidelines for Myelodysplastic Syndromes
Greenberg PL, Bishop M, Deeg J, Erba H, Gore S, & Stone R. (1998). NCCN Practice Guidelines for Myelodysplastic Syndromes. Oncology, 12(11A).

International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LEBEAU, M. M., Fenaux, P., Morel, P., & Bennett, J. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. BLOOD, 89(6), 2079-2088.

Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
Rajapaksa, R., Ginzton, N., Rott, L. S., & Greenberg, P. L. (1996). Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. BLOOD, 88(11), 4275-4287.

GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation
Greenberg, P., Advani, R., Keating, A., Gulati, S. C., Nimer, S., & Cuffie, C. (1996). GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. BONE MARROW TRANSPLANTATION, 18(6), 1057-1064.

Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy
Negrin, R. S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J., & Greenberg, P. L. (1996). Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. BLOOD, 87(10), 4076-4081.

Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes
Greenberg, P. L. (1996). Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. SEMINARS IN HEMATOLOGY, 33(2), 163-175.

Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G-CSF plus erythropoietin: Evidence for in vivo synergy
Negrin RS, Stein R, Doherty K, Cromwell J, Vardiman J, & Greenberg PL. (1996). Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G-CSF plus erythropoietin: Evidence for in vivo synergy. Blood, 87.

ENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT YIELDS FOR TRANSPLANTATION
Schriber, J. R., DEJBAKHSHJONES, S., KUSNIERZGLAZ, C. R., Ginzton, N., Still, B., & Strober, S. (1995). ENRICHMENT OF BONE-MARROW AND BLOOD PROGENITOR (CD34(+)) CELLS BY DENSITY GRADIENTS WITH SUFFICIENT YIELDS FOR TRANSPLANTATION. EXPERIMENTAL HEMATOLOGY, 23(9), 1024-1029.

MODULATION OF APOPTOSIS IN HUMAN MYELOID LEUKEMIC-CELLS BY GM-CSF
Han, J. H., Gileadi, C., Rajapaksa, R., Kosek, J., & Greenberg, P. L. (1995). MODULATION OF APOPTOSIS IN HUMAN MYELOID LEUKEMIC-CELLS BY GM-CSF. EXPERIMENTAL HEMATOLOGY, 23(3), 265-272.

EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR THERAPY ON IN-VITRO HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES
Nagler, A., MacKichan, M. L., Negrin, R. S., Donlon, T., & Greenberg, P. L. (1995). EFFECTS OF GRANULOCYTE-COLONY-STIMULATING FACTOR THERAPY ON IN-VITRO HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES. LEUKEMIA, 9(1), 30-39.

TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN COMBINATION WITH ERYTHROPOIETIN
Negrin, R. S., Stein, R., Vardiman, J., Doherty, K., Cornwell, J., & Greenberg, P. L. (1993). TREATMENT OF THE ANEMIA OF MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN COMBINATION WITH ERYTHROPOIETIN. BLOOD, 82(3), 737-743.

T-CELL SUBSETS AND SUPPRESSOR CELLS IN HUMAN BONE-MARROW
SCHMIDTWOLF, I. Gh., DEJBAKHSHJONES, S., Ginzton, N., Greenberg, P., & Strober, S. (1992). T-CELL SUBSETS AND SUPPRESSOR CELLS IN HUMAN BONE-MARROW. BLOOD, 80(12), 3242-3250.

INVITRO MARROW CULTURE STUDIES IN THE MYELODYSPLASTIC SYNDROMES
Greenberg, P. L. (1992). INVITRO MARROW CULTURE STUDIES IN THE MYELODYSPLASTIC SYNDROMES. SEMINARS IN ONCOLOGY, 19(1), 34-46.

TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS
Greenberg, P. L. (1992). TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS. SEMINARS IN ONCOLOGY, 19(1), 106-114.

Programmed cell death (apoptosis) as a mechanism for regulating haematopoietic cell population size
Greenberg PL. (1992). Programmed cell death (apoptosis) as a mechanism for regulating haematopoietic cell population size. --.

TREATMENT OF MYELODYSPLASTIC SYNDROMES
Greenberg, P. L. (1991). TREATMENT OF MYELODYSPLASTIC SYNDROMES. BLOOD REVIEWS, 5(1), 42-50.

EFFECTS OF INSULIN-LIKE GROWTH-FACTORS ON HEMATOPOIESIS
Greenberg, P. L. (1991). EFFECTS OF INSULIN-LIKE GROWTH-FACTORS ON HEMATOPOIESIS. BLOOD CELLS, 17(2), 344-346.

FUNCTIONAL INTERACTIONS BETWEEN COLONY-STIMULATING FACTORS AND THE INSULIN FAMILY HORMONES FOR HUMAN MYELOID LEUKEMIC-CELLS
Oksenberg, D., DIECKMANN, B. S., & Greenberg, P. L. (1990). FUNCTIONAL INTERACTIONS BETWEEN COLONY-STIMULATING FACTORS AND THE INSULIN FAMILY HORMONES FOR HUMAN MYELOID LEUKEMIC-CELLS. CANCER RESEARCH, 50(20), 6471-6477.

IMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES - COMPARISON BETWEEN RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (CSF) AND GRANULOCYTE-MONOCYTE CSF
Nagler, A., Binet, C., MacKichan, M. L., Negrin, R., Bangs, C., & Greenberg, P. (1990). IMPACT OF MARROW CYTOGENETICS AND MORPHOLOGY ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES - COMPARISON BETWEEN RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (CSF) AND GRANULOCYTE-MONOCYTE CSF. BLOOD, 76(7), 1299-1307.

EFFECTS OF CSFS IN PRELEUKEMIA
Greenberg, P. L., Negrin, R., & Nagler, A. (1990). EFFECTS OF CSFS IN PRELEUKEMIA. BONE MARROW TRANSPLANTATION, 6, 121-126.

MAINTENANCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR
Negrin, R. S., HAEUBER, D. H., Nagler, A., Kobayashi, Y., Sklar, J., & Greenberg, P. L. (1990). MAINTENANCE TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES USING RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR. BLOOD, 76(1), 36-43.

BONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND NATURAL-KILLER-CELLS
Nagler, A., & Greenberg, P. L. (1990). BONE-MARROW CELL MODULATION AND INHIBITION OF MYELOPOIESIS BY LARGE GRANULAR LYMPHOCYTES AND NATURAL-KILLER-CELLS. INTERNATIONAL JOURNAL OF CELL CLONING, 8(3), 171-183.

EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES
Nagler, A., Ginzton, N., Negrin, R., Bang, D., Donlon, T., & Greenberg, P. (1990). EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR ON INVITRO HEMATOPOIESIS IN THE MYELODYSPLASTIC SYNDROMES. LEUKEMIA, 4(3), 193-202.

HEMATOPOIETIC PROGENITOR-CELL EXPRESSION OF THE H-CAM (CD44) HOMING-ASSOCIATED ADHESION MOLECULE
LEWINSOHN, D. M., Nagler, A., Ginzton, N., Greenberg, P., & BUTCHER, E. C. (1990). HEMATOPOIETIC PROGENITOR-CELL EXPRESSION OF THE H-CAM (CD44) HOMING-ASSOCIATED ADHESION MOLECULE. BLOOD, 75(3), 589-595.

EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR
Greenberg, P., Negrin, R., Nagler, A., Vincent, M., & Donlon, T. (1990). EFFECTS OF PROLONGED TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR. INTERNATIONAL JOURNAL OF CELL CLONING, 8, 293-302.

TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR - A PHASE I-II TRIAL
Negrin, R. S., HAEUBER, D. H., Nagler, A., Olds, L. C., Donlon, T., & Greenberg, P. L. (1989). TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR - A PHASE I-II TRIAL. ANNALS OF INTERNAL MEDICINE, 110(12), 976-984.

SELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINANT INTERLEUKIN-2 STIMULATED HUMAN LYMPHOCYTES-T AND NATURAL-KILLER CELLS
Skettino, S., Phillips, J., Lanier, L., Nagler, A., & Greenberg, P. (1988). SELECTIVE GENERATION OF ERYTHROID BURST PROMOTING ACTIVITY BY RECOMBINANT INTERLEUKIN-2 STIMULATED HUMAN LYMPHOCYTES-T AND NATURAL-KILLER CELLS. BLOOD, 71(4), 907-914.

RECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II FOR HUMAN MYELOID LEUKEMIC-CELLS
PEPE, M. G., Ginzton, N. H., Lee, P. Dk., Hintz, R. L., & Greenberg, P. L. (1987). RECEPTOR-BINDING AND MITOGENIC EFFECTS OF INSULIN AND INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II FOR HUMAN MYELOID LEUKEMIC-CELLS. JOURNAL OF CELLULAR PHYSIOLOGY, 133(2), 219-227.

BIOLOGIC NATURE OF THE MYELODYSPLASTIC SYNDROMES
Greenberg, P. L. (1987). BIOLOGIC NATURE OF THE MYELODYSPLASTIC SYNDROMES. ACTA HAEMATOLOGICA, 78, 94-99.

Granulopoiesis in acute myeloid leukemia and preleukemia
Greenberg PL, Nichols WC, & Schrier SL. (1971). Granulopoiesis in acute myeloid leukemia and preleukemia. New Engl J Med, 284.